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Table 1
Variables Total,
N¼77
Regimen 1,
N¼ 60
Regimen 2,
N¼17(%)
P
value
Age, years
median (range)
52(23-69) 52.5(32-69) 52(23-61) 0.40
Female, n (%) 28(36.4) 26(43.3) 2(11.8) 0.017
FISH risk, n(%) 0.55
Low 50(64.9) 40(66.7) 10(58.8)
High 27(35.1) 20(33.3) 7(41.2)
Time from auto
to AHCT, months
median (range)
5.2(3.3-75.2) 5.0(3.0-47.1) 6.3(4.1-75.2) 0.02
Response status
at transplant,n(%)
0.21
CR 23 (29.9) 15 (25.0) 8 (47.1)
PR 47 (61.0) 39 (65.0) 8 (47.1)
SD 7 (9.1) 6 (10.0) 1 (5.9)
CMV reactivation,
n(%)
14 (18.2) 9 (15.0) 5 (29.4) 0.28
Figure 1. Overall survival by conditioning regimen intensity
Figure 2. Progression free survival by FISH risk
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The Clinical Outcome of Allogeneic Hematopoietic Stem
Cell Transplantation (allo-HSCT) for Elderly Philadelphia
Chromosome-Positive (Ph+) Acute Lymphoblastic
Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor
(TKI) : A Single Institute Experience
Noriko Doki, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi,
Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi.Hematology Division, Tokyo Metropolitan Cancer and
Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
Background: Treatment with TKIs has greatly improved the
outcome of patients with Ph+ALL. However most older pa-
tients are excluded from clinical studies, the curative po-
tential of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has not been fully analyzed. We examine the
clinical features and transplant outcome of elderly Ph+ALL
patients in the era of TKI.
Methods: We analyzed the data from 30 Ph+ALL patients
aged 50 years or older who had used TKI before allo-HSCT.
Results: The median age was 59 years (range<r>: 50-71);15
patients (50%) were older than 60 years. Subjects comprised
13 males and 17 females. The disease status at allo-HSCT was
complete remission (CR) in 23 patients and non-CR in 7 pa-
tients. Before HSCT, 23 patients received imatinib-based
chemotherapy, and 7 patients received dasatinib-based
chemotherapy. The majority of the donors were HLA-
matched unrelated (n¼16) and related (n¼6), followed by
mismatched unrelated cord blood (n¼7). Median follow-up
for survivors was 247 days (r:16-4,156). The median HCT
comorbidity index score was 1 (r:0-3). Median white blood
cell count at diagnosis was 26.3109/L(r: 4.2-301.9 109/L).
Type of BCR breakpoint was minor in 23 patients (67%).
Graft-versus-host-disease (GVHD) prophylaxis was calci-
neurin inhibitor-based in all patients (CsA:13 patients,
FK506:17). Eleven patients received reduced-intensity con-
ditioning regimens, nineteen patients received myeloa-
blative conditioning regimens. Themedian duration from the
diagnosis to HSCTwas 197 days (95-763). No patient received
TKIs after HSCT.
The probability of overall survival (OS) and disease free
survival (DFS) at 1 year after HSCT were 46.0% and 42.0%,
respectively. These results were not statistically different
compared to the 35 patients aged under 50 years who had
used TKIs before allogeneic HSCT. Multivariate analysis
showed that the factor to inﬂuence OS was disease status (CR
or nonCR) (p¼0.01). Cumulative incidence of nonrelapse
mortality (NRM) was 23.1% at 100 days after HSCT, and 52.0%
at 1 year. The cumulative incidence of acute graft-versus-
host disease <GVHD> (grade II-zW) and chronic GVHD at 1
year were 51.8% and 23.1%. Four patients relapsed after HSCT
with a median of 329 days (r:112-475 days). The estimated
cumulative incidence of relapse at 1 year was 8%. These
outcomes (OS, DFS, NRM, relapse rate) were not signiﬁcantly
different when stratiﬁed by age groups (under vs. older than
60 years old). Increasing age was not associated with in-
creases in acute or chronic GVHD. All of patients aged more
than 60 years had HCT comorbidity index scores of 2.
Eighteen patients died at 139 days (r:16-1,219). The main
cause of death was infection (10 patients).
Conclusion: Allo-HSCT for elderly Ph+ALL patients may be
one of the promising strategy. Allo-HSCT would be effec-
tive option for carefully selected patients aged 60 or older
with Ph+ALL.397
High Doses of Myeloid Progenitor Cells Induce Tolerance
in the Context of Autologous HSC Transplantation
Yongwu Li, Lei Sun, Jos Domen. Ward Family Heart Center,
Children’s Mercy Hospital, Kansas City, MO
Bone marrow transplantation has the potential to improve
the outcome of many indications other than cancer, but this
is hampered by the associated complications. Myeloid pro-
genitor cells (MP), which produce a transient engraftment
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may help address some of the infectious complications of
BMT, an approach that is being tested in clinical trials. The
fact thatMP can be cryopreserved and can be used effectively
without being MHC matched to the host enables this
approach.
We have reported in preclinical models that we can use MP
to induce speciﬁc and lasting tolerance for solid organ
transplants. In our model, mice (typically BALB/c) are pre-
conditioned and reconstituted with autologous or allogeneic
hematopoietic stem cells (HSC) and allogeneic MP. MP-
matched skin grafts are placed simultaneously and their fate
is followed long-term. We have established that MP induce
speciﬁc tolerance, MP-matched skin grafts are accepted,
while grafts unmatched to the MP, HSC or host are rejected.
MP from Rag2-/-IL2rg-/- mice that are incapable of produc-
ing B cells, T cells or NK cells, establish that only organ-graft
matched myeloid cells are essential for this process. Toler-
ance can be induced by 100,000 MP in the context of allo-
geneic (third party) HSC transplantation. However, we have
previously reported that the same number of MP only pro-
tects skin grafts in approximately 80% of the recipients that
have been given autologous HSC (Transpl Immunol 31:112-
118,2014).
Here we report that while tolerance induction byMP is more
efﬁcient when combined with allogeneic HSC, increasing the
cell dose ensures the same outcome with autologous HSC.
Injection of 40,000 or more Linneg/lo, Sca-1neg, c-Kit+ MP
induces robust tolerance in recipients of allogeneic HSC.
However, similar results can be obtained in the context of
host-autologous HSC by using slightly higher cell doses
(200,000 or more MP are needed to protect all skin grafts).
We conclude that organ matched MP can induce robust
tolerance for simultaneously or subsequently placed solid
organ transplants, without the need for long-term high level,
multi-lineage engraftment. The speciﬁc properties of MP
(they are clinically available, they can be cryopreserved, they
can be used without matching and MP can be expanded ex
vivo) makes these cells of particular interest. They offer a
new approach to the use of BMT to help in improving solid
organ transplantation.398
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Purpose: Vitamin D deﬁciency has been associated with
chronic Graft Versus Host Disease (GVHD), and insufﬁcient
Vitamin D levels have been shown in patients who have
undergone hematopoietic cell transplant (HCT). This pilot
study tests the hypothesis that Vitamin D deﬁciency is
prevalent and is associated with acute GVHD (AGVHD) in the
immediate 90 days after HCT.
Methods: Fifty allogeneic subjects were selected from the
HCT database based on available bio-samples pretransplant,
30 days, and 90 days post HCT, obtained during 2012-2013.
Retrospective clinical data were also obtained. Liquidchromatography-tandem mass spectrometry (LC-MS/MS)
was used to determine 25-OH vitamin D (D2, D3 and total)
levels at the three time-points. Descriptive analysis was
completed using PASW (IBM, V.20).
Results: 50 subjects (25 male, 25 female), mean age 4111
years, 48% white (18% Asian, 34% other), were selected.
AGVHDwas present in 23/49 (w50%) of subjects and 73% had
Vitamin D deﬁciency at baseline (208 ng/ml), signiﬁcantly
decreasing at 30 days (168 ng/ml, p¼.048), and remained
constant at 90 days (1610 ng/ml). Majority of samples were
below threshold for Vitamin D (<25 ng/ml, 77%), however no
signiﬁcant relationship to AGVHDwas detected (p¼.530). For
sex, men had greater proportion with low Vitamin D (83% v
63%) and AGVHD (52% v 42%) than women, though not
reaching signiﬁcance (p¼.193 & p¼.571). For race, all Asian
subjects were below threshold for Vitamin D (9/9) and 4
developed AGVHD (44%).
Conclusion: We identify a signiﬁcant majority of subjects
undergoing HCT have Vitamin D deﬁciency (73%), progress-
ing 30 days post HCT with a disproportionate effect on sex
and race. Although we do not detect an association between
Vitamin D deﬁciency and AGVHD, an appropriately powered
study is needed to determine whether a relationship exists.
Supplementation andmonitoring HCT patients for Vitamin D
deﬁciency is warranted.399
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Regulatory T cell (Treg) therapy provides an alternative
approach to chronic immunosuppression and has shown
promising results in murine models. Translating this
approach into the clinic depends on developing efﬁcient
methods with which to expand human or non-human pri-
mate Tregs in vitro.
At the Columbia Center for Translational Immunology (CCTI)
we have started a pre-clinical bone marrow transplant pro-
gram using the Cynomolgus macaque (CM) monkey model
involving Tregs to promote tolerance to tissues and organs.
We ﬁrst characterized CM Tregs, which have similar
phenotype when compared to human Tregs. 3.67% of CD4 T
cells in the CM co-express high levels of CD25 and FoxP3
(n¼15) and 3.53% express CD25 and are negative for CD127, a
commonly used Treg marker. Similar to human Tregs, CM
Tregs include naïve or resting Tregs (1.63%) and activated
effector Tregs (2.4%) based on CD45RA expression (n¼7). In
vitro CM CD25hiCD127- (FoxP3+) Tregs were found to be
similarly suppressive as human Tregs, supporting the clinical
relevance of the CM model.
We subsequently aimed to expand polyclonal regulatory T
cells (pTregs) in vitro for use in our transplant studies. We
developed four protocols for the expansion of pTregs over
21-56 days. 50-100 thousand CD4+CD8-CD25hi or CD4+CD8-
CD25hiCD127- Tregs were isolated from 20-30mL of blood
and cultured with IL-2, aCD3, rapamycin and either donor
PBMCs, artiﬁcial APCs (L-cells, murine ﬁbroblast expressing
human CD80, CD58 and CD32) or both. 1000-10,000 fold
